Lisa Joldersma advises life sciences and health plan clients on federal and state health policy strategies that advance business priorities.

Lisa is a seasoned, strategic policy professional with 25 years of experience working at the intersection of state and federal health policy, advocacy, and law. Before joining Avalere, Lisa served as senior vice president of policy and research at PhRMA. In this role, she led policy development and analysis relating to the Inflation Reduction Act, Part D, Medicare Advantage, pharmacy benefit manager oversight and reform, commercial health insurance, 340B, health equity, and transparency. Previously, she served as managing director of policy and regulation at the Blue Cross and Blue Shield Association, where she was responsible for policy development, analysis, and advocacy on issues related to Medicare, Medicaid, and the Federal Employee Health Benefits Program. She also served at the Centers for Medicare and Medicaid Services as a senior advisor for legislation and oversight.

Lisa holds a BA, Phi Beta Kappa, in English and political science from Hope College, where she currently sits on the board of trustees. She also holds a JD from the University of Michigan Law School.

Authored Content

State approaches to PDABs and UPLs vary, but all approaches could impact patient access and affordability.

Avalere assessed how health plans may view UPLs, including implementation considerations and impacts on providers and patients (e.g., plan benefit design).

States will commence legislative sessions at the beginning of January. Drug pricing, including payment limits and reference pricing, as well as improved access will be key priorities.

Avalere experts discuss Congress’ ongoing consideration of pharmacy benefit manager (PBM) legislation.

Avalere experts will explore the potential implications of the Inflation Reduction Act (IRA)’s Medicare drug price negotiation program guidance and discuss implementation strategies for the near- and long-term.